BASEL, Switzerland,
Feb. 14 /PRNewswire/ - Neuro-Biotech
Corp. (PINKSHEET: MRES) (OTCQB: MRES). Dr Claude Poulin CEO is
pleased to announce, that, following the Unsolicited Offer received
on February 9, the Company is
currently finalizing their Due Diligence and will be able to
provide further details on the offering company as well as
management conclusion on Tuesday February
15 at 1pm, in the form of a
Press Release.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
CONTACT
Neuro-Biotech Corp.
Dr. Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
Copyright . 14 PR Newswire